MedTrace Logo

DigiPall; a Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care

NCT06615349 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 382

Last updated 2025-07-10

No results posted yet for this study

Summary

The aim of this study is to test if a system consisting of a wearable device measuring heartbeats and steps, together with daily communication with a chatbot on the smartphone asking the patients about their symptoms and giving tips, can reduce unplanned hospital readmissions and improve well-being in advanced cancer and severely ill patients.

Conditions

  • Terminal Illness
  • Terminal Cancer

Interventions

BEHAVIORAL

DigiPall

DigiPall is an intervention combining a sensor-equipped wearable with a chatbot communicating via WhatsApp on the patient's smartphone. Patients will be asked two questions daily for their subjective rating through WhatsApp on their smartphone, worded slightly differently depending on the measured values for steps, heart rate and compliance as well as the patient's answer the day before.

Sponsors & Collaborators

  • Zurich University of Applied Sciences

    collaborator OTHER

  • David Blum

    lead OTHER

Principal Investigators

  • David Blum, MD PhD · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-11
Primary Completion
2027-06-30
Completion
2027-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06615349 on ClinicalTrials.gov